Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
About this episode
Experts discuss the challenges and advancements in treating pediatric patients with C3 glomerulopathy.
Faculty: Richard Lafayette, MD, FACP Faculty: Ankana Daga, MD Complement-mediated kidney diseases such as C3 glomerulopathy (C3G) continue to present significant diagnostic and therapeutic challenges in nephrology for both adult and pediatric patients. Among children, this rare disease can progress to end-stage kidney disease within 10 years of diagnosis. Traditional treatment options include supportive care and immunotherapies, but both approaches are only modestly effective in reducing proteinuria. The approval of complement inhibitors, particularly those directed to C3, is a major treatment advance for C3G, revolutionizing the care of patients in this setting. In this activity, experts in the field of nephrology review the clinical evidence for these therapies and offer practical tips regarding their optimal use in pediatric patients.
People in this episode
Guests: Richard Lafayette, MD, FACP, Ankana Daga, MD
Mentioned in this episode
Organizations: C3 glomerulopathy, nephrology, Complement inhibitors
More episodes of CME
- Counseling Patients on Their Future with Biologics
- Safety in oHCM Therapy: How and When to Transition Treatment?
- Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
- Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
- Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
- The Future of HNSCC: Aligning Teams, Transforming Care
Explore listener stats, chart rankings, contacts and more on the CME podcast page.